Search Within

Matthew David Hellmann

  1. "Meeting abstract"
Formats
  1. Meeting Abstract (210)
Groups
  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (210)
  3. Thoracic Oncology (210)
  4. GSK Faculty (59)
  5. Department of Pathology and Laboratory Medicine (50)
  6. Weinberg Fellows (43)

More Groups

People
  1. Hira Rizvi (46)
  2. Mark Kris (31)
  3. Charles Rudin (27)
  4. Jamie Chaft (27)
  5. Jedd Wolchok (21)
  6. Kathryn Arbour (20)

More People

Years
  1. 2023 (4)
  2. 2022 (10)
  3. 2021 (21)
  4. 2020 (27)
  5. 2019 (30)
  6. 2018 (49)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (40)
  3. Annals of Oncology (23)
  4. Cancer Research (22)
  5. Journal for ImmunoTherapy of Cancer (19)
  6. Oncology Research and Treatment (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (75)
  2. Elsevier Inc. (47)
  3. American Association for Cancer Research (24)
  4. Oxford University Press (24)
  5. Biomed Central Ltd (19)
  6. S. Karger AG (9)

More Publishers

Results (210)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disease-related biomarkers are associated with extended progression free survival after treatment with NEO-PV-01 in combination with anti-PD1 in patients with metastatic cancers
    Meeting Abstract

    Ott, P.; Govindan, R.; Naing, A.; Friedlander, T.; Margolin, K.; Lin, J.; Bhardwaj, N.; Hellmann, M.; Awad, M.; Wanamaker, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
    Meeting Abstract

    Peters, S.; Ramalingam, S. S.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; Sakai, H.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M. D.; Gubens, M. A.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
    Meeting Abstract

    Garon, E. B.; Hellmann, M. D.; Costa, E. C.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; Patnaik, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer
    Meeting Abstract

    Skoulidis, F.; Arbour, K. C.; Hellmann, M. D.; Patil, P. D.; Marmarelis, M. E.; Awad, M. M.; Murray, J. C.; Hellyer, J.; Gainor, J. F.; Dimou, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer
    Meeting Abstract

    Rizvi, H.; Bandlamudi, C.; Schoenfeld, A. J.; Sauter, J. L.; Arbour, K. C.; Beras, A.; Egger, J. V.; Ladanyi, M.; Donoghue, M.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response
    Meeting Abstract

    Reuss, J. E.; Smith, K. N.; Anagnostou, V.; Zhang, J.; Zahurak, M.; Caushi, J.; Chan, H. Y.; Guo, H.; Hellmann, M. D.; Pardoll, D. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project
    Meeting Abstract

    Merino, D. M.; McShane, L.; Butler, M.; Funari, V. A.; Hellmann, M. D.; Chaudhary, R.; Chen, S. J.; Chen, W. S.; Conroy, J. M.; Fabrizio, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer
    Meeting Abstract

    Lai, W. C. V.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Ginsberg, M. S.; Kris, M. G.; Beras, A.; Rekhtman, N.; Poirier, J. T.; Hellmann, M. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors
    Meeting Abstract

    Hellmann, M. D.; Shimizu, T.; Doi, T.; Hodi, F. S.; Rottey, S.; Aftimos, P. G.; Liu, Z. T.; de Mendizabal, N. V.; Szpurka, A. M.; Piao, Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save